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In search of the ideal basal insulin: Does the
new-generation ultra-long-acting insulin,
degludec, provide the answer?
Improving glycemic control without
increasing the risk of hypoglycemia has
been the main crux of the management
of patients with both type 1 and type 2
diabetes mellitus. Nocturnal hypoglyce-
mia and hypoglycemic unawareness has
long been a well-recognised contributor
to morbidity and mortality in type 1 dia-
betes. Hypoglycemia becomes a progres-
sively frequent clinical problem as
patients approach the insulin deficient
end of the spectrum in advanced type 2
diabetes. Recent multicenter studies on
the benefits of intensive glycemic control,
including the Action to Control Cardio-
vascular Risk in Diabetes (ACCORD)
and the Action in Diabetes and Vascular
Disease: Preterax and Diamicron Modi-
fied Release Controlled Evaluation
(ADVANCE)1 studies, showed that
hypoglycemia was an independent pre-
dictor of mortality and an increased risk
of adverse clinical outcomes in patients
with type 2 diabetes.
The challenges of new subcutaneous
insulin therapies to achieve normoglyce-
mia would be to reduce the incidence of
iatrogenic hypoglycemia, minimize exces-
sive weight gain and maintain a good
long-term safety profile, as recent sugges-
tions that insulin might promote cancers,
though not proven, have raised concerns
regarding the safety of exogenous insulin
use.
In The Lancet, two phase 3, open-
label, treat-to-target, non-inferiority
studies examined the use of a new ultra-
long-acting basal insulin, degludec, as
part of a basal–bolus insulin regimen, in
the treatment of patients with type 12
and type 23 diabetes. Insulin degludec,
on subcutaneous injection, forms a depot
of soluble multihexamers from which
monomers are slowly and continuously
absorbed into the circulation by attach-
ment to albumin, giving a long duration
of action of more than 40 h. Pharmaco-
kinetic data showed a flat and stable pro-
file at steady state and a terminal half-life
of more than 25 h, which is five times
longer than that of insulin detemir
(5–7 h) and twice that of insulin glargine
(13 h).
The BEGIN Basal–Bolus Type 12 and
Type 23 trials confirmed non-inferiority
of insulin degludec to insulin glargine in
efficacy and safety. In type 1 diabetes,
glycated hemoglobin (HbA1c) had fallen
by 0.40% points in both degludec and
glargine at 1 year (estimated treatment
difference 0.01, 95% confidence interval
[CI] 0.14 to 0.11). A total of 188 (40%)
and 67 (43%) participants achieved a tar-
get HbA1c of less than 7% (<53 mmols/
mol) from mean baseline values of
7.7 ± 1.0% standard deviation (60.7 ±
11.0 mmols/mol). A 3:1 randomization
ratio was used to ensure adequate expo-
sure to degludec, as required by regula-
tory guidelines. In type 2 diabetes, the
primary end-point of HbA1c reduction at
1 year was 1.1% with degludec and 1.2%
with glargine (estimated treatment differ-
ence 0.08, 95% CI 0.05 to 0.21). The
mean reductions in laboratory-reported
fasting plasma glucose and the nine-point
self-measured plasma glucose were also
similar between treatments, providing
further support of non-inferiority.
The rates of overall confirmed hypo-
glycemia (plasma glucose <3.1 mmol/L
or severe episodes requiring assistance)
were significantly lower with degludec
than glargine in type 2 diabetes, as were
the rates of nocturnal confirmed
hypoglycemia in both type 1 and type 2
diabetes (Table 1).
The lower rates of nocturnal hypo-
glycemia can be explained by an evenly-
distributed exposure (approximately
50:50) to degludec in the first and second
12-h period after once-daily administra-
tion. In contrast, 60% of exposure to
glargine occurs in the first 12 h, which
can lead to more nocturnal hypoglycemia
after bedtime dosing compared with
morning administration. The timing of
insulin glargine dosing was not recorded
in both studies, which might have
affected the estimated risk of nocturnal
hypoglycemia. However, the authors3 dis-
missed the timing effect, as the adminis-
tration of glargine was adherent to its
product labelling (any time, but the same
time each day at the investigator’s discre-
tion). A second explanation for the lower
hypoglycemic rates in these trials lies in
the variability of insulin absorption
from subcutaneous tissue. Subcutaneous
administration of currently available
exogenous insulin does not always result
in a uniformly reproducible metabolic
effect, even when injected at the same
dose under comparable conditions. Insu-
lin degludec has a significantly more pre-
dictable glucose-lowering effect than
glargine, with a four-times less day-to-
day variability compared with glargine at
steady state (using euglycemic glucose
clamps) in type 1 diabetes4. It remains to
be seen if this translates into clinical ben-
efit and whether the lowered variability
extends to patients with type 2 diabetes.
In both trials, nocturnal hypoglycemia
only contributed to 10–15% of all con-
firmed hypoglycemic events. Most of the
hypoglycemic episodes occurred during
daytime hours, probably attributed to the
bolus mealtime insulin aspart. Further-
more, there was no uniform dose
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titration algorithm for the bolus insulin
aspart, as it did for the basal insulins
degludec and glargine. The open-label
design also contributes to the risk of
reporting bias, which might affect the
subjective outcomes, such as symptom-
atic hypoglycemia and quality of life.
Greater caution might also be preferen-
tially given to the dose adjustment of the
new drug, degludec. However, full mask-
ing of treatments was not achievable
because of differences in the delivery
devices.
One of the common patient barriers
to insulin intensification is weight gain.
The present studies showed similar mean
weight gain in both treatment groups in
patients with type 1 diabetes (1.8 kg
[standard error 0.2] with degludec and
1.6 kg [0.3] with glargine, P = 0.62); and
with type 2 diabetes (3.6 kg [standard
deviation 4.9] with degludec and 4.0
[4.6] with glargine). The weight gain in
patients with type 2 diabetes might be
partly ascribed to the increase in total
daily insulin doses, including both basal
and bolus insulins, throughout the trial.
However, total daily insulin doses
decreased in those with type 1 diabetes,
suggesting other contributing factors to
the weight gain. Insulin-related weight
gain might result from a conservation of
ingested calories as improved glycemic
control returns patients to glycemic levels
that are below the renal threshold. Fur-
thermore, insulin exerts an anabolic effect
by inhibiting muscle protein breakdown
and free fatty acid metabolism, inhibiting
lipolysis and promoting lipogenesis. The
defensive increase in caloric intake
because of the fear of or avoidance of
genuine hypoglycemia might also con-
tribute to insulin-related weight gain.
Can insulin degludec become the ideal
basal insulin? The answer will depend on
its long-term efficacy and safety profile.
In both trials, the adverse event rates did
not differ between insulin degludec and
glargine. Most adverse events were mild
or moderate. The rate of injection site
reactions was low (3–5%) in both treat-
ment groups. A low insulin-like growth
factor-1 receptor binding affinity and low
mitogenic activity of insulin degludec
in vitro suggested a molecular safety sim-
ilar to that of human insulin.
Four major adverse cardiovascular
events were reported in the type 1 diabe-
tes trial2, of which three were fatal. One
sudden death was attributed to the treat-
ment of insulin glargine and aspart,
whereas two reported fatal myocardial
infarctions in the degludec group were
deemed to be causally unrelated to treat-
ment. Nonetheless, hypoglycemia-induced
prolonged QT interval is a potential risk
factor for sudden death in diabetes and
should not be overlooked.
Insulin degludec is the first basal ana-
log insulin that can be co-formulated
with the prandial analog insulin aspart5.
The novel premixed insulin (IDegAsp:
70% degludec and 30% aspart) confers a
similar reduction in HbA1c and hypogly-
cemic risk compared with insulin glar-
gine, with the additional advantage of
targeting the fasting and postprandial
glucose increase simultaneously. IDegAsp
would be a promising treatment option
for initiating insulin therapy in patients
with type 2 diabetes inadequately con-
trolled with oral antidiabetic agents.
In summary, the results of two
phase 3 basal–bolus studies in patients
with long-standing type 1 and type 2
diabetes showed that insulin degludec
achieved glycemic control that was simi-
lar to insulin glargine, with reduced noc-
turnal hypoglycemia in both type 1 and
type 2 diabetes, in addition to a reduc-
tion in overall hypoglycemia in type 2
diabetes. The long-acting and flat profile
of insulin degludec potentially offers a
more physiological insulin response akin
to the basal secretory pattern of endoge-
nous b-cells, thus potentially providing
an improved basal insulin in the man-
agement of type 1 and type 2 diabetes.
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